Welcome to our dedicated page for CELL SOURCE news (Ticker: CLCS), a resource for investors and traders seeking the latest updates and insights on CELL SOURCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CELL SOURCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CELL SOURCE's position in the market.
Cell Source (OTCQB:CLCS) presented groundbreaking preclinical findings at the 2024 American Society of Hematology Annual Meeting, demonstrating how their proprietary Veto Cell technology can overcome NK cell-mediated rejection in allogeneic cell therapy. The research shows Veto Tcm cells can suppress NK cell activity without triggering host T-cell proliferation or graft-versus-host disease by down-regulating the DNAM-1 activating receptor on NK cells.
This breakthrough could enable the development of off-the-shelf CAR-T therapies that are safer, more cost-effective, and scalable compared to existing treatments. The technology's ability to suppress NK-mediated rejection represents a significant advancement in addressing current cellular therapy limitations, particularly in facilitating safer mismatched donor stem cell and organ transplantation.
Cell Source (OTCQB:CLCS) has announced promising interim results from its Phase 1/2 First-in-Human clinical trial of Veto Cell technology at MD Anderson Cancer Center. The trial, involving 15 patients with hematologic diseases, demonstrated successful engraftment without severe graft-versus-host disease (GvHD) using T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning. Key findings include consistent engraftment at 42 days post-transplant, no Veto Cell-related toxicity, and an enhanced protocol using mild conditioning with Rituximab. The technology aims to make transformative treatments more accessible for conditions ranging from leukemia to sickle cell disease.
Cell Source, Inc. (OTC: CLCS) announced the appointment of Darlene Soave to its Board of Directors, effective May 25, 2021. Soave brings over 40 years of entrepreneurial leadership experience, previously co-founding Soave Enterprises, which generates over $1.8 billion in annual revenues. This leadership change comes at a pivotal time as Cell Source advances its first Phase I/II clinical trial, aimed at proving the safety and efficacy of its innovative Veto Cell technology, designed for improved stem cell and organ transplants.
Cell Source, Inc. (OTC: CLCS) announced the issuance of two USPTO patents for its innovative Veto Cell technology, enhancing mismatched donor stem cell transplants and treating blood diseases. The first patent focuses on Veto Cells generated from memory T cells, facilitating patient acceptance and fighting infections. The second patent describes Veto Cells as companion cells for CAR-T and NK cell therapies, preventing graft rejection. These advancements position Veto Cells as a versatile immunotherapy platform, with applications in cancer treatment and beyond, bolstering the company's growth potential.
Cell Source (OTC: CLCS) has made significant advancements in Veto Cell based immunotherapy, achieving a key breakthrough in treating sickle cell disease (SCD). Their newly developed mouse model protocol demonstrates durable prevention of SCD pathology, with complete conversion to normal, donor-derived red blood cells. Published in the BMT Journal, this study addresses major challenges in mismatched donor stem cell transplants. The ongoing Phase 1/2 clinical trial is testing Veto Cells for safety and efficacy in hematological diseases, offering hope for safe and effective treatments.
Cell Source, Inc. (OTC: CLCS) announced that Dr. Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is a renowned expert in pediatric hematology-oncology at City of Hope and brings extensive experience in childhood cancer treatments and stem cell transplantation. His addition comes as Cell Source's Veto Cell technology transitions into the first human clinical trials, a significant milestone for the company. Chairman Dennis Brown expressed optimism about Dr. Rosenthal's contributions to advancing their innovative immunotherapy technologies.
FAQ
What is the current stock price of CELL SOURCE (CLCS)?
What is the market cap of CELL SOURCE (CLCS)?
